Finanzen von Protagonist Therapeutics Inc (PTGX)PTGXProtagonist Therapeutics Inc

Evaluating the bottom line, Protagonist Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 74.37%, while the net margin is 76.28%. These profitability ratios, combined with a Return on Equity (ROE) of 10.98%, provide a clear picture of how effectively PTGX converts its operational activities into shareholder value.

In the context of the broader market, PTGX competes directly with industry leaders such as TGTX and CYTK. With a market capitalization of $8.70B, it holds a significant position in the sector. When comparing efficiency, PTGX's gross margin of 100.00% stands against TGTX's 82.86% and CYTK's 80.46%. Such benchmarking helps identify whether Protagonist Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Protagonist Therapeutics reported a profit of $162.8 million in Q2 2026, translating to an EPS of $2.29, a significant turnaround from previous losses. The gross margin remains strong at 100%, indicating effective cost management in their operations.